Načítá se...
An Illustrative Case of Combination Cabozantinib/Nivolumab for Progressive Metastatic Renal Cell Carcinoma (mRCC)
We report a case using combination cabozantinib plus nivolumab to salvage disease control in a patient with refractory metastatic renal cell carcinoma. The patient had previously experienced disease progression from high‐dose interleukin‐2, sunitinib, pazopanib, cabozantinib, and nivolumab, all give...
Uloženo v:
| Vydáno v: | Oncologist |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley & Sons, Inc.
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7930408/ https://ncbi.nlm.nih.gov/pubmed/33251710 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13617 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|